ALEXANDER KHARLAMOV
Founder, C.E.O., and Independent Researcher
M.D., FESC, FACC, FEACVI
De Haar Research Task Force | Foundation (DHRF)
Rotterdam - Amsterdam, The Netherlands | Tallinn, Estonia
Being relocated to the Netherlands in 2022-2025
Fostering High-Quality Honest & Fair Research Perfectionism
DHRF pioneers advanced cardiovascular care and imaging, developing innovative medical devices powered by artificial intelligence, biomedical engineering, and nanomedicine—driving research, innovation, and progress in heart health.
Our Mission
We are dedicated to advancing groundbreaking research in cardiovascular medicine. Our mission is to lead translational and clinical studies, deliver expert-level cardiovascular imaging services, and drive the development of innovative technologies—including AI- and machine learning-based imaging software, medical devices, and cutting-edge solutions in biomedical engineering and nanotechnology.
We actively contribute to shaping national and international healthcare standards in cardiology, with a focus on interventional cardiology and cardiovascular imaging. Through education and outreach, we share knowledge with both the scientific community and the general public.
Above all, we are committed to the highest standards of quality and safety in cardiovascular imaging and therapy, working to dramatically reduce the global burden of cardiovascular disease and save millions of lives.
Advanced Cardiovascular Imaging in Non-Invasive and Interventional Cardiology; Bioresorbable Scaffolds (with Sensors and Nanoparticles)
Cardiovascular Health and Sex Characteristics, Sexual Orientation and Gender Identity
Artificial Womb (Ectogenesis), Same-Sex Gametes In Vitro Fertilization (Degendered Reproduction) and Transhumanism
(Hi-Tech for Reproductive Freedom)
Artificial Intelligence and Public Health in Cardiology, Intelligence Studies and Medical Intelligence
Consciousness and Theory of Everything; Immortality in Singularity; Philosophy of Science
The idea of DHRF was born in Rotterdam on February 15th, 2013. The DHRF develops and supports innovations in interventional cardiology, medical device development, intracoronary/ intravascular (QCA, IVUS, OCT, NIRS, photoacoustic), and non-invasive imaging (CCTA, CMR, MPI, PET, TTE), including artificial intelligence/ machine learning-based technologies, biomedical engineering, neurophysiology (primarily, consciousness), and nanomedicine (multifunctional nanoparticles for theranostics of atherosclerosis). The DHRF provides start-ups and small enterprises in the Netherlands, Estonia, the United States, and countries of the Commonwealth of Nations with the relevant research service and assistance in representing, promoting, and supporting their biomedical business in Europe, as well as the relevant translational and clinical studies including CE mark procedures. The DHRF is an SME business located in Tallinn (Estonia) and Rotterdam - Amsterdam (the Netherlands) with ambitions of further development and expansion inside the Lowlands, Europe, and the United States. We do not collaborate with Russian institutions.
